More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
This Christmas, it’s time to unwrap something priceless: better health. Boehringer Ingelheim Philippines is back with It ...
Inc., together with Dialysis Philippines Support Group (Dialysis PH), Kidney Transplant Association of the Philippines (KITAP ...
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...
Experienced diabetologist and medical director, Dr. Owen brings to DiogenX over two decades of expertise in diabetes clinical management and drug development, as lead candidate progresses towards ...
Twenty-five companies participated in the kickoff meeting of the End-User Counsel, including Boehringer Ingelheim, ContiTech, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback